dual glp-1/gip agonist | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Mechanisms of action of GLP-1

GLP-1 Therapies Outperform Bariatric Surgery in Cancer Risk Reduction A 2025 study published in eClinicalMedicine (Wolff Sagy Y et al.) compared cancer outcomes in patients receiving GLP-1 receptor agonists versus those who had undergone bariatric metabolic surgery

Researchers should consult the full Phase 2 safety data and any updated Phase 3 findings when designing research protocols involving this compound

Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man

doi: 10.1016/S0025-7753(14)70101-0

10.3390/nu7115475 21

Conclusion In conclusion, CVOTs have played a pivotal role in evaluating the cardiovascular safety and efficacy of GLP-1 receptor agonists in patients with T2D